October 2021 Dominique Costantini, Co-Founder of OSE Pharma, invited to « Bpifrance Inno Génération »
October 2021 Presentation of the future entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum »
October 2021 Effimune and OSE Pharma announce the online publication of Preclinical efficacy data for FR104
October 2021 OSE Pharma and Effimune announce the signing of the Merger Treaty to create OSE Immunotherapeutics
October 2021 Fifth country opens recruitment in the global pivotal Phase 3 Trial of the immunotherapy Tedopi® with initiation in Hungary
October 2021 OSE Pharma to Join Workshop “Phase I: An inflection point in drug development and value generation” at BIO-Europe Spring® 2016
October 2021 OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7